11. Biotech NetWorkshop

28. – 29. June 2017, Munich

PRI-002

Priavoid has successfully applied to start a Phase I clinical trial with PRI-002, a drug for the causal treatment of Alzheimer’s disease. A Phase II clinical trial is in preparation and is scheduled to start in 2018.